While often seen as a gift, high intelligence can come with its own unique set of challenges, particularly when navigating a ...

Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of ...

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Living through the pandemic aged our brains faster — even among people who never became sick with COVID-19, according to a ...

SaveHealth reports migraines are complex neurological conditions affecting over a billion globally, requiring comprehensive ...